Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy

References

• Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69:313–317. doi:10.1007/s13304-017-0424-1
   PubMed Web of Science ®Google Scholar
• Hashemzadeh N, Dolatkhah M, Adibkia K, et al. Recent advances in breast cancer immunotherapy: the promising impact of nanomedicines. Life Sci. 2021;271:119110. doi:10.1016/j.lfs.2021.119110
   PubMed Web of Science ®Google Scholar
• McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57(Suppl 1):9S–16S. doi:10.2967/jnumed.115.157834
   PubMed Web of Science ®Google Scholar
• Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22:1408–1415. doi:10.1245/s10434-015-4405-7
   PubMed Web of Science ®Google Scholar
• Zhang X, Li H, Wu F, et al. clinical observation of zhengyuan capsule combined with neoadjuvant chemotherapy for triple-negative breast cancer. Evid Based Complement Alternat Med. 2022;2022:1375724. doi:10.1155/2022/1375724
   PubMed Web of Science ®Google Scholar
• Wang M, Hou L, Chen M, et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. Sci Rep. 2017;7:44673. doi:10.1038/srep44673
   PubMed Web of Science ®Google Scholar
• Huang J, Li H, Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol. 2015;47:840–848. doi:10.3892/ijo.2015.3084
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–1207. doi:10.1016/j.jaci.2017.08.034
   PubMed Web of Science ®Google Scholar
• Si Z, Zhong Y, Lao S, Wu Y, Zhong G, Zeng W. The role of miRNAs in the resistance of anthracyclines in breast cancer: a systematic review. Front Oncol. 2022;12:899145. doi:10.3389/fonc.2022.899145
   PubMed Web of Science ®Google Scholar
• Baldassari F, Zerbinati C, Galasso M, et al. Screen for MicroRNA and drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4/6 and PIK3CA inhibitors. Front Genet. 2018;9:174. doi:10.3389/fgene.2018.00174
   PubMed Web of Science ®Google Scholar
• Cun J, Yang Q. Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Biomed Pharmacother. 2018;107:117–128. doi:10.1016/j.biopha.2018.07.158
   PubMed Web of Science ®Google Scholar
• Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016;107:326–334. doi:10.1111/cas.12880
   PubMed Web of Science ®Google Scholar
• Isca C, Piacentini F, Mastrolia I, et al. Circulating and intracellular miRNAs as prognostic and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy: a review of the literature. Cancers. 2021;13(19):4894. doi:10.3390/cancers13194894
   PubMed Web of Science ®Google Scholar
• Carvalho TM, Brasil GO, Jucoski TS, et al. MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in serum and tissue: potential biomarkers in sporadic breast cancer. Front Genet. 2022;13:865472. doi:10.3389/fgene.2022.865472
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta. 2012;413:1058–1065. doi:10.1016/j.cca.2012.02.016
   PubMed Web of Science ®Google Scholar
• Pimentel F, Bonilla P, Ravishankar YG, et al. Technology in MicroRNA profiling: circulating MicroRNAs as noninvasive cancer biomarkers in breast cancer. J Lab Autom. 2015;20:574–588. doi:10.1177/2211068214561788
   PubMedGoogle Scholar
• Wu H, Wang Q, Zhong H, et al. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. Oncol Rep. 2020;43:240–250. doi:10.3892/or.2019.7401
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang J, Wang B, Zhang H, He J, Wang K. A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer. Sci Rep. 2021;11:11348. doi:10.1038/s41598-021-91049-x
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Y, Ding X, Li W. Identification of lncRNA/circRNA-miRNA-mRNA ceRNA network as biomarkers for hepatocellular carcinoma. Front Genet. 2022;13:838869. PMID: 35386284; PMCID: PMC8977626. doi:10.3389/fgene.2022.838869
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu Y, Shi G. The circRNA-miRNA-mRNA regulatory network in systemic lupus erythematosus. Clin Rheumatol. 2021;40(1):331–339. PMID: 32533339. doi:10.1007/s10067-020-05212-2
   PubMed Web of Science ®Google Scholar
• Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800. doi:10.1016/j.biopha.2019.108800
   PubMed Web of Science ®Google Scholar
• Davey MG, Lowery AJ, Miller N, Kerin MJ. MicroRNA expression profiles and breast cancer chemotherapy. Int J Mol Sci. 2021;22:10812. doi:10.3390/ijms221910812
   PubMed Web of Science ®Google Scholar
• Lou W, Liu J, Ding B, Xu L, Fan W. Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Manag Res. 2018;10:4747–4757. doi:10.2147/CMAR.S172722
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong S, Xu Y, et al. MicroRNA-3646 contributes to docetaxel resistance in human breast cancer cells by GSK-3beta/beta-catenin signaling pathway. PLoS One. 2016;11:e0153194. doi:10.1371/journal.pone.0153194
   PubMed Web of Science ®Google Scholar
• Cojocneanu R, Braicu C, Raduly L, et al. Plasma and tissue specific miRNA expression pattern and functional analysis associated to colorectal cancer patients. Cancers. 2020;12:843. doi:10.3390/cancers12040843
   PubMed Web of Science ®Google Scholar
• Pegoraro A, De Marchi E, Ferracin M, et al. P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis. 2021;12:1088. doi:10.1038/s41419-021-04378-0
   PubMed Web of Science ®Google Scholar
• Usuba W, Urabe F, Yamamoto Y, et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 2019;110:408–419. doi:10.1111/cas.13856
   PubMed Web of Science ®Google Scholar
• Ginsburg OM, Fischer HD, Shah BR, et al. A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario. Curr Oncol. 2015;22:97–104. doi:10.3747/co.22.2359
   PubMed Web of Science ®Google Scholar
• Jiang Z, Guo J, Shen J, Jin M, Xie S, Wang L. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells. J Exp Clin Cancer Res. 2012;31:42. doi:10.1186/1756-9966-31-42
   PubMed Web of Science ®Google Scholar
• Grant E, Bucklain FA, Ginn L, Laity P, Ciani B, Bryant HE. Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines. PLoS One. 2022;17:e0268300. doi:10.1371/journal.pone.0268300
   PubMed Web of Science ®Google Scholar
• Deng ZM, Hu W, Dai FF, Yuan MQ, Hu M, Cheng YX. Immune-related genes to construct a novel prognostic model of breast cancer: a chemosensitivity-based study. Front Immunol. 2021;12:734745. doi:10.3389/fimmu.2021.734745
   PubMed Web of Science ®Google Scholar
• Pires BRB, Panis C, Alves VD, et al. Label-free proteomics revealed oxidative stress and inflammation as factors that enhance chemoresistance in luminal breast cancer. Oxid Med Cell Longev. 2019;2019:5357649. doi:10.1155/2019/5357649
   PubMed Web of Science ®Google Scholar
• Zheng L, Xiang C, Li X, et al. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol Oncol. 2018;11:72. doi:10.1186/s13045-018-0613-5
   PubMed Web of Science ®Google Scholar
• Frederiksen LJ, Sullivan R, Maxwell LR, et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res. 2007;13:2199–2206. doi:10.1158/1078-0432.CCR-06-1807
   PubMed Web of Science ®Google Scholar
• Gao C, Yuan X, Jiang Z, et al. Regulation of AKT phosphorylation by GSK3beta and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat. 2019;176:291–301. doi:10.1007/s10549-019-05239-3
   PubMed Web of Science ®Google Scholar
• Zhou BB. Targeting ligand cleavage to inhibit the ErbB pathway in cancer. Ann N Y Acad Sci. 2005;1059:56–60. doi:10.1196/annals.1339.022
   PubMed Web of Science ®Google Scholar
• Rose DP, Gracheck PJ, Vona-Davis L. The interactions of obesity, inflammation and insulin resistance in breast cancer. Cancers. 2015;7:2147–2168.
   PubMed Web of Science ®Google Scholar
• Castellano E, Molina-Arcas M, Krygowska AA, et al. RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. Nat Commun. 2016;7:11245. doi:10.1038/ncomms11245
   PubMed Web of Science ®Google Scholar
• Afify SM, Seno M. Conversion of stem cells to cancer stem cells: undercurrent of cancer initiation. Cancers. 2019;11:345. doi:10.3390/cancers11030345
   PubMed Web of Science ®Google Scholar